Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study findsExperts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...
Hosted on MSN2mon
Vivani begins exenatide implant trial for obesity in AustraliaVivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback